Cargando…
Modeling of the Aqueous Solubility of N-butyl-N-methyl-1-phenylpyrrolo[1,2-a] pyrazine-3-carboxamide: From Micronization to Creation of Amorphous–Crystalline Composites with a Polymer
N-butyl-N-methyl-1-phenylpyrrole[1,2-a] pyrazine-3-carboxamide (GML-3) is a potential candidate for combination drug therapy due to its anxiolytic and antidepressant activity. The anxiolytic activity of GML-3 is comparable to diazepam. The antidepressant activity of GML-3 is comparable to amitriptyl...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611044/ https://www.ncbi.nlm.nih.gov/pubmed/37896380 http://dx.doi.org/10.3390/polym15204136 |
_version_ | 1785128398968848384 |
---|---|
author | Markeev, Vladimir B. Tishkov, Sergey V. Vorobei, Anton M. Parenago, Olga O. Blynskaya, Evgenia V. Alekseev, Konstantin V. Marakhova, Anna I. Vetcher, Alexandre A. |
author_facet | Markeev, Vladimir B. Tishkov, Sergey V. Vorobei, Anton M. Parenago, Olga O. Blynskaya, Evgenia V. Alekseev, Konstantin V. Marakhova, Anna I. Vetcher, Alexandre A. |
author_sort | Markeev, Vladimir B. |
collection | PubMed |
description | N-butyl-N-methyl-1-phenylpyrrole[1,2-a] pyrazine-3-carboxamide (GML-3) is a potential candidate for combination drug therapy due to its anxiolytic and antidepressant activity. The anxiolytic activity of GML-3 is comparable to diazepam. The antidepressant activity of GML-3 is comparable to amitriptyline. GML-3 is an 18 kDa mitochondrial translocator protein (TSPO) ligand and is devoid of most of the side effects of diazepam, which makes the research on the creation of drugs based on it promising. However, its low water solubility and tendency to agglomerate prevented its release. This research aimed to study the effect of dry grinding, the rapid expansion of a supercritical solution (RESS), and the eutectic mixture (composite) of GML-3 with polyvinylpyrrolidone (PVP) on the particle size, dissolution rate, and lattice retention of GML-3. The use of supercritical CO(2) in the RESS method was promising in terms of particle size reduction, resulting in a reduction in the particle size of GML-3 to 20–40 nm with a 430-fold increase in dissolution rate. However, in addition to particle size reduction after RESS, GML-3 began to show signs of a polymorphism phenomenon, which was also studied in this article. It was found that coarse grinding reduced particle size by a factor of 2 but did not significantly affect solubility or crystal structure. Co-milling with the polymer made it possible to level the effect of the appearance of a residual electrostatic charge on the particles, as in the case of grinding, and the increased solubility in the resulting mechanical mixtures of GML-3 with the polymer may also indicate the dissolving properties of polymers (an increase in 400–800 times). The best result in terms of GML-3 solubility was demonstrated by the resulting GML-3:PVP composite at a ratio of 1:4, which made it possible to achieve a solubility of about 80% active pharmaceutical ingredient (API) within an hour with an increase in the dissolution rate by 1600 times. Thus, the creation of composites is the most effective method for improving the solubility of GML-3, superior to micronization. |
format | Online Article Text |
id | pubmed-10611044 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106110442023-10-28 Modeling of the Aqueous Solubility of N-butyl-N-methyl-1-phenylpyrrolo[1,2-a] pyrazine-3-carboxamide: From Micronization to Creation of Amorphous–Crystalline Composites with a Polymer Markeev, Vladimir B. Tishkov, Sergey V. Vorobei, Anton M. Parenago, Olga O. Blynskaya, Evgenia V. Alekseev, Konstantin V. Marakhova, Anna I. Vetcher, Alexandre A. Polymers (Basel) Article N-butyl-N-methyl-1-phenylpyrrole[1,2-a] pyrazine-3-carboxamide (GML-3) is a potential candidate for combination drug therapy due to its anxiolytic and antidepressant activity. The anxiolytic activity of GML-3 is comparable to diazepam. The antidepressant activity of GML-3 is comparable to amitriptyline. GML-3 is an 18 kDa mitochondrial translocator protein (TSPO) ligand and is devoid of most of the side effects of diazepam, which makes the research on the creation of drugs based on it promising. However, its low water solubility and tendency to agglomerate prevented its release. This research aimed to study the effect of dry grinding, the rapid expansion of a supercritical solution (RESS), and the eutectic mixture (composite) of GML-3 with polyvinylpyrrolidone (PVP) on the particle size, dissolution rate, and lattice retention of GML-3. The use of supercritical CO(2) in the RESS method was promising in terms of particle size reduction, resulting in a reduction in the particle size of GML-3 to 20–40 nm with a 430-fold increase in dissolution rate. However, in addition to particle size reduction after RESS, GML-3 began to show signs of a polymorphism phenomenon, which was also studied in this article. It was found that coarse grinding reduced particle size by a factor of 2 but did not significantly affect solubility or crystal structure. Co-milling with the polymer made it possible to level the effect of the appearance of a residual electrostatic charge on the particles, as in the case of grinding, and the increased solubility in the resulting mechanical mixtures of GML-3 with the polymer may also indicate the dissolving properties of polymers (an increase in 400–800 times). The best result in terms of GML-3 solubility was demonstrated by the resulting GML-3:PVP composite at a ratio of 1:4, which made it possible to achieve a solubility of about 80% active pharmaceutical ingredient (API) within an hour with an increase in the dissolution rate by 1600 times. Thus, the creation of composites is the most effective method for improving the solubility of GML-3, superior to micronization. MDPI 2023-10-18 /pmc/articles/PMC10611044/ /pubmed/37896380 http://dx.doi.org/10.3390/polym15204136 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Markeev, Vladimir B. Tishkov, Sergey V. Vorobei, Anton M. Parenago, Olga O. Blynskaya, Evgenia V. Alekseev, Konstantin V. Marakhova, Anna I. Vetcher, Alexandre A. Modeling of the Aqueous Solubility of N-butyl-N-methyl-1-phenylpyrrolo[1,2-a] pyrazine-3-carboxamide: From Micronization to Creation of Amorphous–Crystalline Composites with a Polymer |
title | Modeling of the Aqueous Solubility of N-butyl-N-methyl-1-phenylpyrrolo[1,2-a] pyrazine-3-carboxamide: From Micronization to Creation of Amorphous–Crystalline Composites with a Polymer |
title_full | Modeling of the Aqueous Solubility of N-butyl-N-methyl-1-phenylpyrrolo[1,2-a] pyrazine-3-carboxamide: From Micronization to Creation of Amorphous–Crystalline Composites with a Polymer |
title_fullStr | Modeling of the Aqueous Solubility of N-butyl-N-methyl-1-phenylpyrrolo[1,2-a] pyrazine-3-carboxamide: From Micronization to Creation of Amorphous–Crystalline Composites with a Polymer |
title_full_unstemmed | Modeling of the Aqueous Solubility of N-butyl-N-methyl-1-phenylpyrrolo[1,2-a] pyrazine-3-carboxamide: From Micronization to Creation of Amorphous–Crystalline Composites with a Polymer |
title_short | Modeling of the Aqueous Solubility of N-butyl-N-methyl-1-phenylpyrrolo[1,2-a] pyrazine-3-carboxamide: From Micronization to Creation of Amorphous–Crystalline Composites with a Polymer |
title_sort | modeling of the aqueous solubility of n-butyl-n-methyl-1-phenylpyrrolo[1,2-a] pyrazine-3-carboxamide: from micronization to creation of amorphous–crystalline composites with a polymer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611044/ https://www.ncbi.nlm.nih.gov/pubmed/37896380 http://dx.doi.org/10.3390/polym15204136 |
work_keys_str_mv | AT markeevvladimirb modelingoftheaqueoussolubilityofnbutylnmethyl1phenylpyrrolo12apyrazine3carboxamidefrommicronizationtocreationofamorphouscrystallinecompositeswithapolymer AT tishkovsergeyv modelingoftheaqueoussolubilityofnbutylnmethyl1phenylpyrrolo12apyrazine3carboxamidefrommicronizationtocreationofamorphouscrystallinecompositeswithapolymer AT vorobeiantonm modelingoftheaqueoussolubilityofnbutylnmethyl1phenylpyrrolo12apyrazine3carboxamidefrommicronizationtocreationofamorphouscrystallinecompositeswithapolymer AT parenagoolgao modelingoftheaqueoussolubilityofnbutylnmethyl1phenylpyrrolo12apyrazine3carboxamidefrommicronizationtocreationofamorphouscrystallinecompositeswithapolymer AT blynskayaevgeniav modelingoftheaqueoussolubilityofnbutylnmethyl1phenylpyrrolo12apyrazine3carboxamidefrommicronizationtocreationofamorphouscrystallinecompositeswithapolymer AT alekseevkonstantinv modelingoftheaqueoussolubilityofnbutylnmethyl1phenylpyrrolo12apyrazine3carboxamidefrommicronizationtocreationofamorphouscrystallinecompositeswithapolymer AT marakhovaannai modelingoftheaqueoussolubilityofnbutylnmethyl1phenylpyrrolo12apyrazine3carboxamidefrommicronizationtocreationofamorphouscrystallinecompositeswithapolymer AT vetcheralexandrea modelingoftheaqueoussolubilityofnbutylnmethyl1phenylpyrrolo12apyrazine3carboxamidefrommicronizationtocreationofamorphouscrystallinecompositeswithapolymer |